<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 获取免费报告) 的股价在周三的午盘交易中下跌了 3.6%。该股最低交易价格为 15.00 美元，最后交易价格为 15.05 美元。午盘交易中成交了 157,665 股，较平均交易量 76,094 股增加了 107%。该股此前收盘价为 15.61 美元。</p>
<p>获取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
<h2>分析师设定新目标价</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Coeptis Therapeutics 股票的 “卖出（e+）” 评级。一位研究分析师对该股给予了卖出评级，根据 MarketBeat 的数据，该股的共识评级为 “卖出”。</p>
<p><strong>查看我们关于 Coeptis Therapeutics 的最新研究报告</strong></p>
<h2>Coeptis Therapeutics 股票下跌 3.6%</h2>
<p>该股市值为 8037 万美元，市盈率为-5.26，贝塔值为-0.53。该公司 50 日移动平均线为 15.78 美元，200 日移动平均线为 12.76 美元。公司的流动比率为 2.21，速动比率为 2.21，债务股本比率为 0.01。</p>
<p>Coeptis Therapeutics (NASDAQ:COEP - 获取免费报告) 最近于 11 月 13 日发布了季度财报。该公司报告本季度每股收益（EPS）为-0.58 美元。该公司本季度的收入为 24 万美元。</p>
<h2>对 Coeptis Therapeutics 的对冲基金看法</h2>
<p>一家对冲基金最近在 Coeptis Therapeutics 股票中购买了新股份。Yorkville Advisors Global LP 在第三季度收购了 Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 免费报告) 的新股份，根据该公司最近向证券交易委员会提交的 13F 文件，该公司收购了 8,000 股，价值约 14 万美元。Coeptis Therapeutics 在 Yorkville Advisors Global LP 的投资组合中占比约为 0.0%，是其第 24 大持仓。Yorkville Advisors Global LP 在最近一个季度末持有 Coeptis Therapeutics 的 0.17%。13.88% 的股票由机构投资者和对冲基金持有。</p>
<h2>Coeptis Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Coeptis Therapeutics Holdings, Inc.是一家生物制药公司，开发针对癌症患者的细胞治疗平台。其产品组合包括 CD38-GEAR-NK，一种用于治疗与 CD38 相关的癌症的细胞治疗，包括多发性骨髓瘤、慢性淋巴细胞白血病和急性髓性白血病；SNAP-CAR，一种与标记的肿瘤特异性抗体共同管理的 CAR T 细胞治疗平台，可能针对不同类型的肿瘤，包括血液恶性肿瘤和实体瘤；以及 CD38-Diagnostic，一种体外筛查工具，用于分析癌症患者是否可能适合接受抗 CD38 单克隆抗体治疗。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票而非 Coeptis Therapeutics</li>
<li>10 美元以下的最佳股票</li>
<li>市场动量：3 只有望大幅突破的股票</li>
<li>在经济衰退中与这些分红之王共度难关</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
<li>什么是分红挑战者？</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Coeptis Therapeutics 吗？</h2>
<p>在你考虑 Coeptis Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Coeptis Therapeutics 并不在名单上。</p>
<p>虽然 Coeptis Therapeutics 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

COEP

<p>Coeptis Therapeutics（纳斯达克代码：COEP）股价在午盘交易中下跌了 3.6%，交易量显著增加。分析师已给予 “卖出” 评级，该公司的市值为 8037 万美元。尽管最近对对冲基金的关注增加，Coeptis Therapeutics 并未成为分析师推荐的顶级股票之一</p>

<p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Get Free Report)'s share price fell 3.6% during mid-day trading on Wednesday . The stock traded as low as $15.00 and last traded at $15.05. 157,665 shares traded hands during mid-day trading, an increase of 107% from the average session volume of 76,094 shares. The stock had previously closed at $15.61.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 获取免费报告) 的股价在周三的午盘交易中下跌了 3.6%。该股最低交易价格为 15.00 美元，最后交易价格为 15.05 美元。午盘交易中成交了 157,665 股，较平均交易量 76,094 股增加了 107%。该股此前收盘价为 15.61 美元。</p>
</div><p>Get <strong>Coeptis Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Coeptis Therapeutics</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Coeptis Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Coeptis Therapeutics 股票的 “卖出（e+）” 评级。一位研究分析师对该股给予了卖出评级，根据 MarketBeat 的数据，该股的共识评级为 “卖出”。</p>
</div><p><strong>Check Out Our Latest Research Report on Coeptis Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Coeptis Therapeutics 的最新研究报告</strong></p>
</div><h2>Coeptis Therapeutics Stock Down 3.6%</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 股票下跌 3.6%</h2>
</div><p>The stock has a market capitalization of $80.37 million, a price-to-earnings ratio of -5.26 and a beta of -0.53. The firm has a 50-day moving average of $15.78 and a 200 day moving average of $12.76. The company has a current ratio of 2.21, a quick ratio of 2.21 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>该股市值为 8037 万美元，市盈率为-5.26，贝塔值为-0.53。该公司 50 日移动平均线为 15.78 美元，200 日移动平均线为 12.76 美元。公司的流动比率为 2.21，速动比率为 2.21，债务股本比率为 0.01。</p>
</div><p>Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.58) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million for the quarter.</p>
<div class="lb-trans"><p>Coeptis Therapeutics (NASDAQ:COEP - 获取免费报告) 最近于 11 月 13 日发布了季度财报。该公司报告本季度每股收益（EPS）为-0.58 美元。该公司本季度的收入为 24 万美元。</p>
</div><h2>Hedge Funds Weigh In On Coeptis Therapeutics</h2>
<div class="lb-trans"><h2>对 Coeptis Therapeutics 的对冲基金看法</h2>
</div><p>A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,000 shares of the company's stock, valued at approximately $140,000. Coeptis Therapeutics makes up about 0.0% of Yorkville Advisors Global LP's investment portfolio, making the stock its 24th biggest position. Yorkville Advisors Global LP owned 0.17% of Coeptis Therapeutics at the end of the most recent quarter. 13.88% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家对冲基金最近在 Coeptis Therapeutics 股票中购买了新股份。Yorkville Advisors Global LP 在第三季度收购了 Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP - 免费报告) 的新股份，根据该公司最近向证券交易委员会提交的 13F 文件，该公司收购了 8,000 股，价值约 14 万美元。Coeptis Therapeutics 在 Yorkville Advisors Global LP 的投资组合中占比约为 0.0%，是其第 24 大持仓。Yorkville Advisors Global LP 在最近一个季度末持有 Coeptis Therapeutics 的 0.17%。13.88% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Coeptis Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Coeptis Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.</p>
<div class="lb-trans"><p>Coeptis Therapeutics Holdings, Inc.是一家生物制药公司，开发针对癌症患者的细胞治疗平台。其产品组合包括 CD38-GEAR-NK，一种用于治疗与 CD38 相关的癌症的细胞治疗，包括多发性骨髓瘤、慢性淋巴细胞白血病和急性髓性白血病；SNAP-CAR，一种与标记的肿瘤特异性抗体共同管理的 CAR T 细胞治疗平台，可能针对不同类型的肿瘤，包括血液恶性肿瘤和实体瘤；以及 CD38-Diagnostic，一种体外筛查工具，用于分析癌症患者是否可能适合接受抗 CD38 单克隆抗体治疗。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Coeptis Therapeutics</li>
<li>Best Stocks Under $10.00</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>Ride Out The Recession With These Dividend Kings</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>What Are Dividend Challengers?</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Coeptis Therapeutics</li>
<li>10 美元以下的最佳股票</li>
<li>市场动量：3 只有望大幅突破的股票</li>
<li>在经济衰退中与这些分红之王共度难关</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
<li>什么是分红挑战者？</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Coeptis Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Coeptis Therapeutics 吗？</h2>
</div><p>Before you consider Coeptis Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Coeptis Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Coeptis Therapeutics 并不在名单上。</p>
</div><p>While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Coeptis Therapeutics 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Coeptis Therapeutics（NASDAQ:COEP）股价下跌 3.6% - 现在是卖出的时候吗？